Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug 1:13:956519.
doi: 10.3389/fimmu.2022.956519. eCollection 2022.

Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report

Xiaojun Ye  1 , Xiangliang Liu  1 , Na Yin  1 , Wei Song  1 , Jin Lu  1 , Yi Yang  1 , Xiao Chen  1
Affiliations
Case Reports

Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report

Xiaojun Ye et al. Front Immunol. .

Abstract

Background: Multiple Primary Malignancies (MPMs) refer to the occurrence of two or more primary malignancies in the same organ or multiple organs and tissues of the same patient simultaneously or sequentially, with an incidence rate ranging from 2-17%. According to the difference in the time of occurrence of each primary tumor, MPMs can be classified as simultaneous malignancies and heterochronic malignancies. The former refers to the occurrence of two or more malignancies one after another within 6 months, while the latter refers to the occurrence of two malignancies at an interval of more than 6 months. Currently, there is a lack of effective treatment options for MPMs both nationally and internationally.

Case presentation: The patient was a 65-year-old male smoker with a definite diagnosis of advanced lung adenocarcinoma with kirsten rat sarcoma viral oncogene (KRAS) mutation, concomitant with primary renal clear cell carcinoma (RCCC), who had a progression-free survival (PFS) for 7 months after first-line treatment with albumin-bound paclitaxel and cisplatin in combination with sintilimab.

Conclusion: In this paper, we report a case of advanced lung adenocarcinoma combined with RCCC as a concurrent double primary malignancy, which achieved a satisfactory outcome after first-line chemotherapy combined with immunotherapy, with the aim of exploring effective treatment modalities for this type of MPMs, in order to improve the survival and prognosis of the patient.

Keywords: chemotherapy; immunotherapy; lung adenocarcinoma; multiple primary malignancies; renal clear cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
CT of the lungs at different times. (A–D) Mediastinal Window; (E–F) window of lung fields. (A) Pulmonary lesion before treatment. (B) CT revealed a stable disease after 2 cycles of albumin-bound paclitaxel and cisplatin in combination with sintilimab. (C) CT revealed a stable disease after 6 cycles of albumin-bound paclitaxel and cisplatin in combination with sintilimab. (D) CT showed no significant changes in the primary lesion of the left lung after sequential 2 cycles of sintilimab immune monotherapy maintenance treatment. (E)The window of lung fields after 6 cycles of albumin-bound paclitaxel and cisplatin in combination with sintilimab. (F) CT revealed pulmonary metastases increased after sequential 2 cycles of sintilimab immune monotherapy maintenance treatment (as the red arrow).
Figure 2
Figure 2
Abdominal CT at different times. (A) The left kidney lesion before treatment. (B) CT revealed a stable disease after 2 cycles of albumin-bound paclitaxel and cisplatin in combination with sintilimab. (C) CT revealed a stable disease after 6 cycles of albumin-bound paclitaxel and cisplatin in combination with sintilimab. (D) No significant change in left kidney lesion after sequential 2 cycles of sintilimab immune monotherapy maintenance treatment.
Figure 3
Figure 3
Whole body bone imaging showed increased radioactivity in the third thoracic vertebra with bone destruction.
Figure 4
Figure 4
Tissue sections stained with hematoxylin-eosin. (A) Adenocarcinoma of the left lung. (B) Left renal clear cell carcinoma.
Figure 5
Figure 5
PD-L1 protein expression on tumor cells was detected by VENTATA PD-L1(SP263). (A) The results was negative. (B) The results was negative.
Figure 6
Figure 6
Time flow chart of the diagnosis and treatment process of this patient. (C2 represents 2 courses of treatment, C4 represents 4 courses of treatment, C6 represents 6 courses of treatment, C2 maintenance therapy represents 2 courses of maintenance therapy).
Figure 7
Figure 7
Changes in tumor marker content. Cytokeratin 19 fragment, CEA, CA125 and NSE were abnormally increased before treatment, after 2 courses of treatment, cytokeratin 19 fragment and NSE decreased significantly. After 6 courses of treatment, CEA and CA125 also decreased significantly.
Figure 8
Figure 8
Changes of peripheral blood inflammatory indexes. The content of ANC, CRP and the ratio of NRL gradually decreased after treatment.
Figure 9
Figure 9
Changes in the proportion of T cells in peripheral blood. With the treatment progressed, the content of CD3+ and CD3+CD4+ increased until the end of 6 courses of treatment.
See this image and copyright information in PMC

References

    1. Zheng R, Zhang S, Zeng H, Wang S, Sun K, He J, et al. . Cancer incidence and mortality in China, 2016. J Natl Cancer Center (2022). doi: 10.1016/j.jncc.2022.02.002 - DOI - PMC - PubMed
    1. Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. Targeted therapies in early stage NSCLC: hype or hope? Int J Mol Sci (2020) 21(17):6329. doi: 10.3390/ijms21176329 - DOI - PMC - PubMed
    1. Marostica E, Barber R, Denize T, Kohane IS, Signoretti S, Golden JA, et al. . Development of a histopathology informatics pipeline for classification and prediction of clinical outcomes in subtypes of renal cell carcinoma. Clin Cancer Res (2021) 27(10):2868–78. doi: 10.1158/1078-0432.CCR-20-4119 - DOI - PubMed
    1. Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol (2021) 17(4):245–61. doi: 10.1038/s41581-020-00359-2 - DOI - PMC - PubMed
    1. Sato S, Shinohara N, Suzuki S, Harabayashi T, Koyanagi T. Multiple primary malignancies in Japanese patients with renal cell carcinoma. Int J Urol (2004) 11(5):269–75. doi: 10.1111/j.1442-2042.2004.00792.x. - DOI - PubMed

Publication types

MeSH terms